When the Spinal Cord Is Under Immune Attack: The Case for a 20-Marker Myelopathy Panel

Autoimmune Neurology Series

India’s only validated 7-marker MG panel – and what our national dataset of 388 cases reveals about the diagnostic information lost when clinicians test for only two antibodies.

ZeiniX Life Sciences Autoimmune Neurology Diagnostics | India

Expert Perspective

A patient presents with rapidly ascending weakness, sensory loss below a spinal level, and bladder dysfunction progressing over days. The MRI shows a long T2 lesion spanning four vertebral segments with cord swelling. The first differential on the list is tuberculosis of the spine – a reasonable reflex in India. Anti-tuberculosis therapy is started. The patient does not improve.

Weeks later, the correct diagnosis emerges: an autoimmune myelopathy driven by a specific neural autoantibody, one that is not only treatable but reversible with the right immunotherapy – if caught early enough. By then, some of the neurological damage is permanent.

This clinical scenario is not rare. It is the rule, not the exception, in the current Indian diagnostic environment – where immune-mediated myelopathy is systematically underdiagnosed, misdiagnosed as TB or MS, and inadequately investigated because the right tools either do not exist or are not being used.

Myelopathy is an increasingly recognised presentation of many antibody-mediated neuroinflammatory disorders. Every case deserves a systematic antibody screen – not reflexive anti-tubercular therapy and watchful waiting.

The Diagnostic Problem: A Wide Differential, a Narrow Reflex

Immune-mediated myelopathies are a broad and mechanistically heterogeneous group of conditions. They share a final common pathway – spinal cord inflammation – but differ fundamentally in their underlying antibody targets, their clinical course, their risk of relapse, and crucially, their optimal treatment. A patient with AQP4-IgG-positive NMOSD requires long-term immunosuppression to prevent catastrophic relapses. A patient with MOG-IgG-associated myelopathy needs a different treatment algorithm. A patient with a paraneoplastic myelopathy may have an occult malignancy that requires urgent oncological investigation Identifying the correct antibody does not just refine the diagnosis – it determines the treatment. And yet, in the absence of a validated, comprehensive autoantibody screen, clinicians are left making decisions in the dark.

ZeiniX Life Sciences , in collaboration with the Neuro-Immunology Lab at the Department of Neurology, Amrita Institute of Medical Sciences, Cochin, has now introduced India’s first 20-marker comprehensive antibody panel for the diagnosis of immune-mediated spinal cord inflammation.

Recognising the Patient Who Needs Testing: Clinical Red Flags

Not every myelopathy is autoimmune. But the following clinical features, individually or in combination, should immediately prompt autoantibody testing – before committing to alternative diagnoses or empirical therapies.

Sub-acute progression over days to weeks - autoimmune injury evolves rapidly, unlike the indolent course of degenerative or compressive myelopathy.

Longitudinally extensive transverse myelitis (LETM) spanning more than three vertebral segments - a hallmark of AQP4-IgG and MOG-IgG disease, rarely seen in MS or infection.

Co-existing optic neuritis, encephalitis, meningitis signs, or conus involvement - overlap syndromes are common in NMOSD and MOGAD; a spinal lesion rarely exists in isolation.

MRI showing cord swelling with T2 hyperintensity - inflammatory oedema in an active immune attack, distinct from the cord atrophy of degenerative disease.

Poor response to antibiotics or anti-tubercular therapy - treatment failure is a critical signal that the working diagnosis is wrong.

Recurrent myelitis episodes - relapsing course is the defining feature of several autoimmune myelopathies; each relapse compounds permanent disability without suppressive therapy.

The presence of even one of these features should be sufficient to initiate autoantibody testing in parallel with other investigations – not after all other avenues have been exhausted.

The ZeiniX 20-Marker Autoimmune Myelopathy Panel

The ZeiniX panel was designed to be comprehensive – to cover the full spectrum of known neural autoantibodies implicated in immune-mediated myelopathy, including NMOSD, paraneoplastic syndromes, and rare but treatable conditions that are frequently missed on partial panels.

The panel can be tested in both serum and CSF, giving clinicians flexibility based on clinical context. One marker – VGCC – is offered exclusively in serum.

The twenty markers are grouped below by their primary diagnostic utility:

Markers covering NMOSD, paraneoplastic, and rare autoimmune myelopathies

1st

Panel of this breadth introduced in India for immune-mediated myelopathy

Sample types accepted — serum and CSF — for maximum diagnostic flexibility

Why Each Category of Marker Matters Clinically

NMOSD: THE HIGHEST-STAKES DIAGNOSIS IN MYELOPATHY

Neuromyelitis optica spectrum disorder, defined by antibodies against aquaporin-4 (AQP4-IgG) or myelin oligodendrocyte glycoprotein (MOG-IgG), is arguably the most consequential autoimmune myelopathy to diagnose – and to correctly differentiate. AQP4-IgG disease carries a relapsing course in the vast majority of untreated patients, with each attack potentially leaving irreversible motor and sensory deficits. The treatment strategy – long-term complement inhibition, B-cell depletion, or IL-6 pathway blockade – is specific to NMOSD and is not appropriate for MS. MOG-IgG disease has a different natural history, different treatment considerations, and different prognosis. Differentiating these two entities, and distinguishing both from MS, requires confirmed antibody testing. Neither clinical features nor MRI are sufficient alone.

PARANEOPLASTIC ANTIBODIES: THE SPINAL CORD AS A CANCER SIGNAL

A subset of immune-mediated myelopathies are paraneoplastic – the immune attack on the spinal cord is triggered by an underlying malignancy, most commonly small cell lung cancer, breast cancer, ovarian cancer, thymoma, or testicular cancer. The neural antibody is produced as part of a misdirected anti-tumour immune response. In this context, the autoantibody is not just diagnostic of a neurological condition – it is a tumour marker. Identifying ANNA1, ANNA2, PCA1, CRMP5, KLHL11, or VGCC positivity in a patient with myelopathy mandates urgent oncological investigation, often before any neurological symptoms can be attributed to a known cancer. The panel detects occult malignancy at its earliest, most treatable stage.

CLINICAL URGENCY

In paraneoplastic myelopathy, the neurological condition and the underlying cancer must be treated in parallel. Immunotherapy alone, without tumour removal or treatment, will not sustainably control the immune attack. The antibody screen is therefore not merely diagnostic – it is oncologically urgent.

GAD65 AND GLYRΑ1: TREATABLE STIFFNESS SYNDROMES HIDING IN PLAIN SIGHT

Two of the panel’s markers deserve particular attention for their clinical relevance in the Indian setting. Anti-GAD65 antibodies are associated with stiff person syndrome – a condition characterised by progressive muscle rigidity, painful spasms, and hyperlordosis – as well as cerebellar ataxia and, in some patients, myelopathy. This is a treatable condition that is frequently misattributed to a movement disorder or psychiatric disease. Anti-GlyRα1 (glycine receptor alpha-1) antibodies are associated with progressive encephalomyelitis with rigidity and myoclonus (PERM) – another condition that responds to immunotherapy when identified correctly. Both conditions are rare, recognisable with testing, and treatable. Without the panel, patients may spend years undiagnosed.

GFAP ASTROCYTOPATHY: THE MENINGOENCEPHALOMYELITIS THAT MIMICS EVERYTHING

Autoimmune GFAP (glial fibrillary acidic protein) astrocytopathy is a recently characterised condition that presents with a combination of meningitis, encephalitis, and myelitis – often with a characteristic linear perivascular enhancement pattern on MRI. It is exquisitely responsive to corticosteroids, with excellent functional recovery when treated early. It is also significantly underdiagnosed because GFAP testing is not routinely included in most commercial neuroinflammatory panels. Its inclusion in the ZeiniX myelopathy panel closes this gap.

The Logic of Comprehensive Testing: Why Antibody Identity Determines Treatment

The fundamental principle that underpins the ZeiniX autoimmune myelopathy panel is this: in immune-mediated neurological disease, the antibody drives the treatment decision. This is not a nuance – it is the clinical reality.

Rapid identification of treatable causes

Many autoimmune myelopathies respond dramatically to early immunotherapy. Weeks of diagnostic delay translate directly into additional irreversible axonal injury. Early antibody identification enables early treatment.

Prevention of misdiagnosis as MS or TB

The two most common misdiagnoses in Indian patients with autoimmune myelopathy are TB and MS. Neither condition is treated the same way. Misdiagnosis means wrong treatment - and continued immune injury.

Enables targeted long-term therapy

NMOSD requires lifelong immunosuppression. MOGAD may not. Paraneoplastic conditions require tumour treatment. GAD65 disease requires IVIG or rituximab. The antibody identity determines whether - and how - to commit to long-term treatment.

Correct antibody = correct drug

IVIG for MOGAD. Rituximab or eculizumab for AQP4+NMOSD. Corticosteroids for GFAP astrocytopathy. Diazepam and IVIG for GAD65 stiff person syndrome. These are not interchangeable choices.

Detection of occult cancer early

Paraneoplastic antibodies may be detectable months before the underlying tumour is radiologically apparent. A positive result initiates oncological investigation at the earliest possible moment.

Reduces the "idiopathic" burden

Discovery of new autoantibodies detectable in serum or CSF progressively reduces the proportion of patients who receive an uninformative "idiopathic" myelitis label - and opens the door to specific immunotherapy.

Correct antibody equals correct drug. This is not a principle unique to autoimmune myelopathy – it is the central logic of all precision immunotherapy. The panel is not a luxury. It is the mechanism by which treatment decisions are made rationally.

The India-Specific Diagnostic Gap

India carries a disproportionate burden of infectious neurological disease – TB, viral encephalitis, neurocysticercosis – and this has shaped a diagnostic culture that defaults, understandably, to infectious aetiologies. But autoimmune myelopathy is not rare in Indian patients. What is rare is the infrastructure to identify it correctly.

The consequences of this gap are measurable. Patients with NMOSD, misdiagnosed as TB myelopathy, receive anti-tubercular therapy that neither helps nor harms the immune process – while the relapsing disease accumulates damage unchecked. Patients with paraneoplastic myelopathy receive symptomatic treatment while the underlying cancer goes undetected. Patients with GFAP astrocytopathy – one of the most treatment-responsive autoimmune myelopathies – deteriorate on watchful waiting because the diagnosis is never reached.

The ZeiniX 20-marker panel, validated and run at the Neuro-Immunology Lab at Amrita Institute of Medical Sciences, Cochin, represents the first time that a genuinely comprehensive autoantibody screen for myelopathy has been available as a routine clinical investigation in India. The samples – serum or CSF – are collected at the referring centre and reach a laboratory with the technical expertise, the validated assays, and the positive control library required to interpret results correctly.

What Clinicians and Patients Should Know

KEY PRINCIPLES FOR ORDERING AND INTERPRETING THE PANEL

Test early – autoimmune myelopathy is a neurological emergency. Antibody testing should be initiated at first presentation, not after empirical treatment has failed.

Test both serum and CSF when clinical suspicion is high – some antibodies, particularly MOG-IgG and GFAP, may be detected at higher titres or with greater sensitivity in CSF. Paired testing increases diagnostic yield.

A positive paraneoplastic antibody mandates oncological investigation regardless of whether a cancer has been detected – the antibody may precede radiological evidence of tumour by months.

A negative result on a comprehensive panel is clinically meaningful – it substantially reduces the probability of antibody-mediated myelopathy and supports investigation of alternative causes, including infectious, vascular, or metabolic aetiologies.

Antibody titre matters – particularly for MOG-IgG, where low titres on cell-based assays require careful clinical correlation. Results from the ZeiniX panel are reported with titres and validated cut-offs, not binary positive/negative calls alone

Conclusion: The Spinal Cord Cannot Wait

Autoimmune myelopathy is treatable. In many cases, it is reversible – but only if diagnosed before the window of recovery narrows. The spinal cord has limited regenerative capacity. Delays of weeks to months during which the immune attack continues unchecked translate into deficits that persist for life: paraplegia, incontinence, intractable pain.

The tools to prevent this outcome now exist and are available in India. The ZeiniX 20-marker Autoimmune Myelopathy Panel, run in collaboration with the Neuro-Immunology Lab at Amrita Institute of Medical Sciences, Cochin, provides a validated, comprehensive, and clinically actionable antibody screen for every patient presenting with the clinical features of immune-mediated spinal cord disease.

The question is not whether to test. In a patient with sub-acute myelopathy, LETM, or recurrent spinal attacks, the question is only how quickly the test can be initiated – and whether the result will reach the clinician in time to change the course of the disease.

ZeiniX Life Sciences is India’s dedicated autoimmune neurology diagnostics laboratory. The 20-marker Autoimmune Myelopathy Panel is validated and processed at the Neuro-Immunology Lab, Department of Neurology, Amrita Institute of Medical Sciences, Cochin. Marketed by ZeiniX Life Sciences Pvt. Ltd. For sample pick-up and clinical inquiries: Customer Care +91 8867759300 | support@zeinixlife.com